- Home
- LVTX vs SER Comparison
LVTX vs SER Comparison
Compare LVTX & SER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LVTX
- SER
- Stock Information
- Founded
- LVTX 2016
- SER 2017
- Country
- LVTX Netherlands
- SER United States
- Employees
- LVTX N/A
- SER N/A
- Industry
- LVTX Biotechnology: Pharmaceutical Preparations
- SER Biotechnology: Pharmaceutical Preparations
- Sector
- LVTX Health Care
- SER Health Care
- Exchange
- LVTX Nasdaq
- SER Nasdaq
- Market Cap
- LVTX 40.0M
- SER 42.0M
- IPO Year
- LVTX 2021
- SER 2018
- Fundamental
- Price
- LVTX $1.64
- SER $3.92
- Analyst Decision
- LVTX Hold
- SER Strong Buy
- Analyst Count
- LVTX 4
- SER 2
- Target Price
- LVTX $1.58
- SER $13.00
- AVG Volume (30 Days)
- LVTX 131.8K
- SER 19.5K
- Earning Date
- LVTX 11-06-2025
- SER 11-13-2025
- Dividend Yield
- LVTX N/A
- SER N/A
- EPS Growth
- LVTX N/A
- SER N/A
- EPS
- LVTX N/A
- SER N/A
- Revenue
- LVTX $4,990,000.00
- SER $116,000.00
- Revenue This Year
- LVTX N/A
- SER $134.46
- Revenue Next Year
- LVTX N/A
- SER N/A
- P/E Ratio
- LVTX N/A
- SER N/A
- Revenue Growth
- LVTX N/A
- SER N/A
- 52 Week Low
- LVTX $0.85
- SER $3.70
- 52 Week High
- LVTX $2.00
- SER $7.92
- Technical
- Relative Strength Index (RSI)
- LVTX 62.46
- SER 40.00
- Support Level
- LVTX $1.60
- SER $3.68
- Resistance Level
- LVTX $1.83
- SER $4.12
- Average True Range (ATR)
- LVTX 0.07
- SER 0.30
- MACD
- LVTX 0.01
- SER 0.00
- Stochastic Oscillator
- LVTX 65.28
- SER 28.65
About LVTX LAVA Therapeutics N.V.
LAVA Therapeutics NV isa clinical stage immuno-oncology company. It is focused on transforming cancer treatment by developing a platform to selectively induce bispecific antibody utilizing the Gammabody platform for an undisclosed tumor associated antigen for the treatment of cancer. Company's pipeline include's products such as LAVA-1266, LAVA-1427, LAVA-1433, LAVA-1207, PF08046052, JNJ89853413.
About SER Serina Therapeutics Inc.
Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers. The Company has one reportable segment relating to the research and development of its POZ platform.